PERFORMANCE OUTCOMES AT 3-MONTHS FOLLOWING IMPLANTATION OF A NEW HYDROPHOBIC TRIFOCAL INTRAOCULAR LENS: RESULTS OF A MULTICENTRIC PROSPECTIVE STUDY

Published 2025 - 29th ESCRS Winter Meeting

Reference: PO198 | Type: Free Paper | DOI: 10.82333/10qh-gr88

Authors: Florian Tobias Alwin Kretz* ¹ , Gerd Auffarth ²

¹Ophthalmology,Precise Vision Augenärzte,Rheine,Germany, ²Ophthalmology,IVCRC,Heidelberg,Germany;Ophthalmology,University Ophthalmology Hospital,Heidelberg,Germany

Purpose

To report the 3-month visual outcomes of patients bilaterally implanted with a new hydrophobic trifocal intraocular lens (

AT ELANA 841P).

Setting

Multicentric, prospective, open-label study.

Methods

Patients received the new IOL following cataract or refractive lens exchange surgery. Study endpoints included monocular and binocular uncorrected and distance-corrected visual acuities (VA) for distance (UDVA, CDVA, 4m), intermediate (80 cm, UIVA, DCIVA), and near (UNVA, DCNVA, 40 cm),

mean refractive spherical equivalent (MRSE)

and defocus curve. Patient-reported satisfaction, spectacle independence and visual disturbances were also measured.

Results

Twenty-nine patients were included in this 3M interim analysis. Mean monocular CDVA (primary endpoint) was

0.00 ± 0.09 logMAR. Mean binocular UDVA, UIVA and UNVA were

-0.01

0.06,

0.05

0.08 and 0.15

0.11 LogMAR, respectively. DCIVA and DCNVA were 0.06

0.08 and 0.13

0.12 LogMAR, respectively.

MRSE was 0.14

0.37 D and 46.6% of the eyes were within ±0.25D of prediction error. Binocular photopic defocus curve showed that all VAs from -3.5 to 1.5 D were <0.04 logMAR. Most patients (89.3%) were satisfied with their vision at 3M, and 92.9% reported to see well without glasses or any other corrective devices. Halos, starbursts and glares were “usually” or “always” reported for 42.8%, 21.4% and 22.7% of the patients, respectively.

Conclusion

All distance, intermediate and near VAs were

<0.2 logMAR at the 3M follow-up visit, and patient satisfaction regarding their vision was high (89.3%). These results showed that AT ELANA 841P can provide excellent vision to patients at all distances.